Source: China News Network
On January 27, the Comprehensive Report of the United States Modena Pharmaceutical Company announced on the 26th that it had begun a clinical trial to study the safety and efficacy of vaccine enhancement needles specifically for the Omikejong variant. A few days ago, the US pharmaceutical company Pfizer and its partner German drug company BioNTech also announced that they have begun testing the new version of the vaccine specifically for the Opichron variant.
Data chart: On December 14, 2020, local time, nurses at the Jewish Medical Center in Long Island, New York, demonstrated the first batch of COVID-19 vaccines in the United States. On the same day, Pfizer's first batch of nearly 3 million doses of COVID-19 vaccines arrived in various parts of the United States. Photo by Liao Pan, a reporter from China News Service
On the 26th local time, the United States Modena Pharmaceutical Company (Moderna) announced that it has begun a clinical trial to study the safety and efficacy of vaccines specifically aimed at Omi kerong. The company said the first participant in the phase II trial had received a booster for Ami kerong.
In addition, Pfizer and BioNTech plan to test the immune response produced by the Omicron-based vaccine, in which unvaccinated subjects will receive three injections, and subjects who have already received two doses of the vaccine will receive booster injections. The two companies are expected to recruit more than 1400 subjects.
Pfizer CEO Bra has said that the Omiljung strain has led to a large number of breakthrough infection cases among vaccinated populations in many places, resulting in a surge in new crown infection cases. He argues that a vaccine directly against Opmi kerong will reduce the risk of a highly contagious but mildly infected similar COVID-19 variant leading to a breakthrough infection.
WHO has previously said the level of risk associated with the outbreak in Opmi kerong remains high. Reuters said the Omiljunn variant may have escaped some of the protection provided by the first two doses of the vaccine.